Literature DB >> 9133446

Significance of telomerase activity in the diagnosis of small differentiated hepatocellular carcinoma.

R Nakashio1, M Kitamoto, H Tahara, T Nakanishi, T Ide, G Kajiyama.   

Abstract

Precise diagnosis of well-differentiated hepatocellular carcinoma (HCC) is sometimes difficult to establish. Telomerase activity was examined by telomeric-repeat-amplification protocol (TRAP) in 37 HCC nodules smaller than 3 cm in diameter, including 24 fine-needle-aspiration biopsy specimens, 22 non-tumor chronic-liver-disease tissues (9 chronic hepatitis and 13 liver cirrhosis) and 3 normal liver tissues. Telomerase activity was assayed by serially diluted samples and quantitated by using an internal telomerase assay standard (ITAS). Telomerase activity was detected in all HCC and in 11 of 22 non-tumor chronic-liver-disease tissues. Normal liver samples had undetectable telomerase activity. Cut-off level of telomerase activity for its practical usage in HCC diagnosis was tentatively set for 0.6 microg liver protein/assay at 10-cell equivalent activity of a gastric-cancer cell line, MKN-1. This level was twice the highest activity in non-tumor chronic liver disease therefore, telomerase activity in all non-tumor liver samples was below this level. The telomerase-positive incidence exceeding this cut-off level was 73% (11/15) in well-differentiated HCC, 94% (16/17) in moderately differentiated HCC and 100% (5/5) in poorly differentiated HCC. Well-differentiated HCC showed low positivity by other diagnostic markers. 21% by AFP, 0% by PIVKA-II and 13% by angiography. The detection of telomerase activity may thus be a useful additional tool for precise and early diagnosis of small differentiated HCC, even when diagnosis is inconclusive by conventional techniques.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9133446     DOI: 10.1002/(sici)1097-0215(19970422)74:2<141::aid-ijc1>3.0.co;2-z

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Telomerase activity, cell proliferation, and cancer.

Authors:  C W Greider
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

2.  Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas.

Authors:  Y Murakami; K Saigo; H Takashima; M Minami; T Okanoue; C Bréchot; P Paterlini-Bréchot
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

3.  Biomarkers for hepatocellular carcinoma.

Authors:  Goshi Shiota; Norimasa Miura
Journal:  Clin J Gastroenterol       Date:  2012-04-26

4.  Prognostic impact of telomerase activity in non-small cell lung cancers.

Authors:  S Taga; T Osaki; A Ohgami; H Imoto; K Yasumoto
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

5.  Telomerase inhibition and telomere loss in BEL-7404 human hepatoma cells treated with doxorubicin.

Authors:  Ru-Gang Zhang; Li-Xia Guo; Xing-Wang Wang; Hong Xie
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

6.  Inhibitory effect of all-trans retinoic acid on human hepatocellular carcinoma cell proliferation.

Authors:  Yun-Feng Piao; Yang Shi; Pu-Jun Gao
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

7.  The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerosis.

Authors:  Xi-Xian Yao; Lei Yin; Zhong-Cheng Sun
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

8.  A novel biomarker TERTmRNA is applicable for early detection of hepatoma.

Authors:  Norimasa Miura; Yukio Osaki; Miki Nagashima; Michimori Kohno; Kensho Yorozu; Kohei Shomori; Takamasa Kanbe; Kenji Oyama; Yukihiro Kishimoto; Shigeo Maruyama; Eijiro Noma; Yutaka Horie; Masatoshi Kudo; Seigo Sakaguchi; Yasuaki Hirooka; Hisao Ito; Hironaka Kawasaki; Junichi Hasegawa; Goshi Shiota
Journal:  BMC Gastroenterol       Date:  2010-05-18       Impact factor: 3.067

9.  High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma.

Authors:  E Hiyama; H Yamaoka; T Matsunaga; Y Hayashi; H Ando; S Suita; H Horie; M Kaneko; F Sasaki; K Hashizume; A Nakagawara; N Ohnuma; T Yokoyama
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

10.  Surgical significance of telomerase activity in noncancerous liver tissue from patients with hepatocellular carcinoma.

Authors:  T Kanamaru; Y Morita; T Itoh; M Yamamoto; Y Kuroda; H Hisatomi
Journal:  Jpn J Cancer Res       Date:  1998-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.